Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-27

AUTHORS

Heather Katz, Layana Biglow, Mohamed Alsharedi

ABSTRACT

BackgroundUpper gastrointestinal (UGI) malignancies including esophageal, gastroesophageal junction (GEJ), and gastric cancers have a poor prognosis in the metastatic setting. Treatment with cytotoxic chemotherapy remains the treatment of choice in the first-line setting with the addition of trastuzumab, a monoclonal antibody against HER-2, if the tumor is HER2-positive. Before the era of checkpoint inhibitors, there were only few treatment options after failure of the first-line systemic therapy.MethodsWe extensively searched the English written literature for peer-reviewed manuscripts regarding the use of checkpoint inhibitors in advanced stage and metastatic UGI cancer. We also searched and reviewed ongoing clinical trials from Clinicaltrials.gov.ResultsCheckpoint inhibition is a promising therapeutic option in UGI cancers, which have overexpression of PD-L1, high mutation burden, or microsatellite instability. Checkpoint inhibitors that are being investigated or are approved in advanced UGI malignancies include PD-1 antibodies, nivolumab and pembrolizumab, PD-L1 antibody, avelumab, and CTLA-4 inhibitors, ipilimumab and tremelimumab.ConclusionsBased on recent and ongoing studies, eligible patients who have progressed beyond the first-line cytotoxic chemotherapy may benefit from immunotherapy. This review outlines the checkpoint inhibitors that are currently or previously being investigated for patients with metastatic UGI cancers. More... »

PAGES

611-619

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12029-019-00243-8

DOI

http://dx.doi.org/10.1007/s12029-019-00243-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113753879

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31028537


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immune Checkpoint Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.259676.9", 
          "name": [
            "Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katz", 
        "givenName": "Heather", 
        "id": "sg:person.011543016727.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543016727.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.259676.9", 
          "name": [
            "Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Biglow", 
        "givenName": "Layana", 
        "id": "sg:person.013022711655.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013022711655.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Joan C. Edwards School of Medicine, Marshall University, Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.259676.9", 
          "name": [
            "Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA", 
            "Division of Hematology and Oncology, Joan C. Edwards School of Medicine, Marshall University, Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alsharedi", 
        "givenName": "Mohamed", 
        "id": "sg:person.01037220762.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037220762.97"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11864-015-0336-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039382020", 
          "https://doi.org/10.1007/s11864-015-0336-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature20805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045212192", 
          "https://doi.org/10.1038/nature20805"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-017-0511-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090956210", 
          "https://doi.org/10.1186/s13045-017-0511-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047946992", 
          "https://doi.org/10.1038/nrc3239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature13480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035707124", 
          "https://doi.org/10.1038/nature13480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep37933", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014345584", 
          "https://doi.org/10.1038/srep37933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-014-0360-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038880236", 
          "https://doi.org/10.1007/s10120-014-0360-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-27", 
    "datePublishedReg": "2019-04-27", 
    "description": "BackgroundUpper gastrointestinal (UGI) malignancies including esophageal, gastroesophageal junction (GEJ), and gastric cancers have a poor prognosis in the metastatic setting. Treatment with cytotoxic chemotherapy remains the treatment of choice in the first-line setting with the addition of trastuzumab, a monoclonal antibody against HER-2, if the tumor is HER2-positive. Before the era of checkpoint inhibitors, there were only few treatment options after failure of the first-line systemic therapy.MethodsWe extensively searched the English written literature for peer-reviewed manuscripts regarding the use of checkpoint inhibitors in advanced stage and metastatic UGI cancer. We also searched and reviewed ongoing clinical trials from Clinicaltrials.gov.ResultsCheckpoint inhibition is a promising therapeutic option in UGI cancers, which have overexpression of PD-L1, high mutation burden, or microsatellite instability. Checkpoint inhibitors that are being investigated or are approved in advanced UGI malignancies include PD-1 antibodies, nivolumab and pembrolizumab, PD-L1 antibody, avelumab, and CTLA-4 inhibitors, ipilimumab and tremelimumab.ConclusionsBased on recent and ongoing studies, eligible patients who have progressed beyond the first-line cytotoxic chemotherapy may benefit from immunotherapy. This review outlines the checkpoint inhibitors that are currently or previously being investigated for patients with metastatic UGI cancers.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12029-019-00243-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297362", 
        "issn": [
          "1941-6628", 
          "1941-6636"
        ], 
        "name": "Journal of Gastrointestinal Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "51"
      }
    ], 
    "keywords": [
      "checkpoint inhibitors", 
      "UGI cancer", 
      "gastrointestinal malignancies", 
      "gastroesophageal junction", 
      "first-line systemic therapy", 
      "CTLA-4 inhibitors", 
      "immune checkpoint inhibitors", 
      "addition of trastuzumab", 
      "PD-1 antibody", 
      "upper gastrointestinal malignancies", 
      "PD-L1 antibodies", 
      "treatment of choice", 
      "ongoing clinical trials", 
      "promising therapeutic option", 
      "high mutation burden", 
      "UGI malignancy", 
      "eligible patients", 
      "metastatic setting", 
      "cytotoxic chemotherapy", 
      "systemic therapy", 
      "PD-L1", 
      "poor prognosis", 
      "therapeutic options", 
      "treatment options", 
      "clinical trials", 
      "gastric cancer", 
      "mutation burden", 
      "peer-reviewed manuscripts", 
      "advanced stage", 
      "microsatellite instability", 
      "malignancy", 
      "cancer", 
      "monoclonal antibodies", 
      "antibodies", 
      "chemotherapy", 
      "patients", 
      "inhibitors", 
      "ongoing studies", 
      "treatment", 
      "ipilimumab", 
      "tremelimumab", 
      "nivolumab", 
      "immunotherapy", 
      "prognosis", 
      "trastuzumab", 
      "HER2", 
      "options", 
      "therapy", 
      "tumors", 
      "MethodsWe", 
      "trials", 
      "burden", 
      "inhibition", 
      "overexpression", 
      "failure", 
      "review", 
      "setting", 
      "study", 
      "junction", 
      "use", 
      "stage", 
      "literature", 
      "addition", 
      "manuscript", 
      "choice", 
      "era", 
      "English", 
      "instability"
    ], 
    "name": "Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies", 
    "pagination": "611-619", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113753879"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12029-019-00243-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31028537"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12029-019-00243-8", 
      "https://app.dimensions.ai/details/publication/pub.1113753879"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_820.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12029-019-00243-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12029-019-00243-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12029-019-00243-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12029-019-00243-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12029-019-00243-8'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      21 PREDICATES      106 URIs      91 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12029-019-00243-8 schema:about N2b2e0a965e6d4b43ae1782049bc0968a
2 N33cadebaf5f545e9a7efc0367c9d5a1c
3 N620234e129474744aac016f94d8aaf72
4 N8e898377c9ec4a1c95d1db769be09f93
5 N92bce0742ae5432bbbd7dbc2a3968f4e
6 Nf373287a21be43c7a261b8dd59214a7f
7 anzsrc-for:11
8 anzsrc-for:1112
9 schema:author Na6fed7a2a9ae462a83a2184b7365a9f5
10 schema:citation sg:pub.10.1007/s10120-014-0360-4
11 sg:pub.10.1007/s11864-015-0336-6
12 sg:pub.10.1038/nature13480
13 sg:pub.10.1038/nature20805
14 sg:pub.10.1038/nrc3239
15 sg:pub.10.1038/srep37933
16 sg:pub.10.1186/s13045-017-0511-2
17 schema:datePublished 2019-04-27
18 schema:datePublishedReg 2019-04-27
19 schema:description BackgroundUpper gastrointestinal (UGI) malignancies including esophageal, gastroesophageal junction (GEJ), and gastric cancers have a poor prognosis in the metastatic setting. Treatment with cytotoxic chemotherapy remains the treatment of choice in the first-line setting with the addition of trastuzumab, a monoclonal antibody against HER-2, if the tumor is HER2-positive. Before the era of checkpoint inhibitors, there were only few treatment options after failure of the first-line systemic therapy.MethodsWe extensively searched the English written literature for peer-reviewed manuscripts regarding the use of checkpoint inhibitors in advanced stage and metastatic UGI cancer. We also searched and reviewed ongoing clinical trials from Clinicaltrials.gov.ResultsCheckpoint inhibition is a promising therapeutic option in UGI cancers, which have overexpression of PD-L1, high mutation burden, or microsatellite instability. Checkpoint inhibitors that are being investigated or are approved in advanced UGI malignancies include PD-1 antibodies, nivolumab and pembrolizumab, PD-L1 antibody, avelumab, and CTLA-4 inhibitors, ipilimumab and tremelimumab.ConclusionsBased on recent and ongoing studies, eligible patients who have progressed beyond the first-line cytotoxic chemotherapy may benefit from immunotherapy. This review outlines the checkpoint inhibitors that are currently or previously being investigated for patients with metastatic UGI cancers.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N7bcf5bdf7c48499aaece5c4df52fd8c0
23 Nbade86306e6b472aae3fa28ed7780564
24 sg:journal.1297362
25 schema:keywords CTLA-4 inhibitors
26 English
27 HER2
28 MethodsWe
29 PD-1 antibody
30 PD-L1
31 PD-L1 antibodies
32 UGI cancer
33 UGI malignancy
34 addition
35 addition of trastuzumab
36 advanced stage
37 antibodies
38 burden
39 cancer
40 checkpoint inhibitors
41 chemotherapy
42 choice
43 clinical trials
44 cytotoxic chemotherapy
45 eligible patients
46 era
47 failure
48 first-line systemic therapy
49 gastric cancer
50 gastroesophageal junction
51 gastrointestinal malignancies
52 high mutation burden
53 immune checkpoint inhibitors
54 immunotherapy
55 inhibition
56 inhibitors
57 instability
58 ipilimumab
59 junction
60 literature
61 malignancy
62 manuscript
63 metastatic setting
64 microsatellite instability
65 monoclonal antibodies
66 mutation burden
67 nivolumab
68 ongoing clinical trials
69 ongoing studies
70 options
71 overexpression
72 patients
73 peer-reviewed manuscripts
74 poor prognosis
75 prognosis
76 promising therapeutic option
77 review
78 setting
79 stage
80 study
81 systemic therapy
82 therapeutic options
83 therapy
84 trastuzumab
85 treatment
86 treatment of choice
87 treatment options
88 tremelimumab
89 trials
90 tumors
91 upper gastrointestinal malignancies
92 use
93 schema:name Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies
94 schema:pagination 611-619
95 schema:productId N35f1930c5c794e93acd556c4113929dc
96 Ne2e087581fc747528f618848c443b054
97 Nf2a4c82e70194abf9b8f52ecd8f87ab9
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113753879
99 https://doi.org/10.1007/s12029-019-00243-8
100 schema:sdDatePublished 2022-11-24T21:04
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N8b19b29342194175bf2171318b770c27
103 schema:url https://doi.org/10.1007/s12029-019-00243-8
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N1eeeaf7d8fd34cfbb1804e2326aed5a6 rdf:first sg:person.01037220762.97
108 rdf:rest rdf:nil
109 N2b2e0a965e6d4b43ae1782049bc0968a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Immune Checkpoint Inhibitors
111 rdf:type schema:DefinedTerm
112 N33cadebaf5f545e9a7efc0367c9d5a1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Progression-Free Survival
114 rdf:type schema:DefinedTerm
115 N35f1930c5c794e93acd556c4113929dc schema:name dimensions_id
116 schema:value pub.1113753879
117 rdf:type schema:PropertyValue
118 N620234e129474744aac016f94d8aaf72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Cohort Studies
120 rdf:type schema:DefinedTerm
121 N7bcf5bdf7c48499aaece5c4df52fd8c0 schema:issueNumber 2
122 rdf:type schema:PublicationIssue
123 N8b19b29342194175bf2171318b770c27 schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N8e898377c9ec4a1c95d1db769be09f93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Neoplasm Metastasis
127 rdf:type schema:DefinedTerm
128 N92bce0742ae5432bbbd7dbc2a3968f4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Gastrointestinal Neoplasms
130 rdf:type schema:DefinedTerm
131 N9efc55d36ba0450fb90d0e03e3de1aea rdf:first sg:person.013022711655.07
132 rdf:rest N1eeeaf7d8fd34cfbb1804e2326aed5a6
133 Na6fed7a2a9ae462a83a2184b7365a9f5 rdf:first sg:person.011543016727.10
134 rdf:rest N9efc55d36ba0450fb90d0e03e3de1aea
135 Nbade86306e6b472aae3fa28ed7780564 schema:volumeNumber 51
136 rdf:type schema:PublicationVolume
137 Ne2e087581fc747528f618848c443b054 schema:name doi
138 schema:value 10.1007/s12029-019-00243-8
139 rdf:type schema:PropertyValue
140 Nf2a4c82e70194abf9b8f52ecd8f87ab9 schema:name pubmed_id
141 schema:value 31028537
142 rdf:type schema:PropertyValue
143 Nf373287a21be43c7a261b8dd59214a7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
150 schema:name Oncology and Carcinogenesis
151 rdf:type schema:DefinedTerm
152 sg:journal.1297362 schema:issn 1941-6628
153 1941-6636
154 schema:name Journal of Gastrointestinal Cancer
155 schema:publisher Springer Nature
156 rdf:type schema:Periodical
157 sg:person.01037220762.97 schema:affiliation grid-institutes:grid.259676.9
158 schema:familyName Alsharedi
159 schema:givenName Mohamed
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037220762.97
161 rdf:type schema:Person
162 sg:person.011543016727.10 schema:affiliation grid-institutes:grid.259676.9
163 schema:familyName Katz
164 schema:givenName Heather
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543016727.10
166 rdf:type schema:Person
167 sg:person.013022711655.07 schema:affiliation grid-institutes:grid.259676.9
168 schema:familyName Biglow
169 schema:givenName Layana
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013022711655.07
171 rdf:type schema:Person
172 sg:pub.10.1007/s10120-014-0360-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038880236
173 https://doi.org/10.1007/s10120-014-0360-4
174 rdf:type schema:CreativeWork
175 sg:pub.10.1007/s11864-015-0336-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039382020
176 https://doi.org/10.1007/s11864-015-0336-6
177 rdf:type schema:CreativeWork
178 sg:pub.10.1038/nature13480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035707124
179 https://doi.org/10.1038/nature13480
180 rdf:type schema:CreativeWork
181 sg:pub.10.1038/nature20805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045212192
182 https://doi.org/10.1038/nature20805
183 rdf:type schema:CreativeWork
184 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
185 https://doi.org/10.1038/nrc3239
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/srep37933 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014345584
188 https://doi.org/10.1038/srep37933
189 rdf:type schema:CreativeWork
190 sg:pub.10.1186/s13045-017-0511-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090956210
191 https://doi.org/10.1186/s13045-017-0511-2
192 rdf:type schema:CreativeWork
193 grid-institutes:grid.259676.9 schema:alternateName Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
194 Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, 25701, Huntington, WV, USA
195 Division of Hematology and Oncology, Joan C. Edwards School of Medicine, Marshall University, Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA
196 schema:name Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
197 Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, 25701, Huntington, WV, USA
198 Division of Hematology and Oncology, Joan C. Edwards School of Medicine, Marshall University, Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...